MK-3000
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
No clinical trials on ClinicalTrials.gov
No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
This drug's own stage for Diabetic Macular Edema: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| MK-3000: this drug | Stage not on record | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Eylea) | Approved | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Abzv (Enzeevu) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Ayyh (Pavblu) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Boav (Eydenzelt) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Jbvf (Yesafili) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Mrbb (Ahzantive) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept-Yszy (Opuviz) | Approved | Protein / enzyme therapeutic | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Brolucizumab-Dbll | Approved | Antibody fragment | VEGF-A | Partial signal | No reviewed efficacy summary in this indication | |
| Faricimab | Approved | Multispecific antibody | Angiopoietin-2 / VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Lucentis) | Approved | Antibody fragment | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Eqrn (Cimerli) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Hkdz (Ranluspec) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab-Leyk (Nufymco) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| RC28-E | Phase 3 | Protein / enzyme therapeutic | VEGF-A / FGF-2 (dual blockade) | Partial signal | NCT05885503: Primary endpoint, mean BCVA change at week 52: non-inferior to aflibercept 2.0 mg (316 subjects) (2025-09-30). | |
| Tabirafusp Tedromer | Phase 3 | Multispecific antibody | VEGF + IL-6 | not yet graded | No reviewed efficacy summary in this indication | |
| BI 1815368 | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| MS-553 | Phase 1 | Small molecule | Protein kinase C-beta (PKC-beta) | not yet graded | No reviewed efficacy summary in this indication | |
| RG6209 | —(overall) | Antibody fragment | — | not yet graded | No reviewed efficacy summary in this indication | |
| RG6697 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| RG6913 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.